Q2 EPS Forecast for Unicycive Therapeutics Lifted by Analyst

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Investment analysts at Brookline Capital Markets raised their Q2 2026 earnings per share estimates for shares of Unicycive Therapeutics in a research report issued to clients and investors on Thursday, May 14th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings per share of ($0.30) for the quarter, up from their previous forecast of ($0.34). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.35) per share. Brookline Capital Markets also issued estimates for Unicycive Therapeutics’ Q3 2026 earnings at ($0.34) EPS and Q4 2026 earnings at ($0.28) EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its earnings results on Tuesday, May 12th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.08).

UNCY has been the topic of a number of other reports. Guggenheim restated a “buy” rating and issued a $37.00 price target (down from $40.00) on shares of Unicycive Therapeutics in a report on Wednesday, May 13th. Benchmark cut their price target on Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating on the stock in a report on Monday, April 6th. Wall Street Zen downgraded Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Westpark Capital began coverage on Unicycive Therapeutics in a research report on Thursday, February 19th. They issued a “buy” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Friday, March 27th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Unicycive Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Unicycive Therapeutics Trading Down 1.3%

UNCY stock opened at $8.15 on Tuesday. The business’s 50-day moving average price is $7.15 and its two-hundred day moving average price is $6.43. The firm has a market cap of $217.61 million, a PE ratio of -3.69 and a beta of 1.78. Unicycive Therapeutics has a 1-year low of $3.71 and a 1-year high of $11.00.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of institutional investors have recently bought and sold shares of UNCY. Millennium Management LLC acquired a new position in Unicycive Therapeutics during the fourth quarter worth approximately $5,856,000. Vivo Capital LLC lifted its stake in Unicycive Therapeutics by 57.4% during the third quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock worth $7,804,000 after purchasing an additional 652,901 shares during the last quarter. Cantor Fitzgerald L. P. bought a new stake in Unicycive Therapeutics during the fourth quarter worth $1,154,000. Dimensional Fund Advisors LP bought a new stake in Unicycive Therapeutics during the first quarter worth $940,000. Finally, Squarepoint Ops LLC bought a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at $512,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.